Bernhard Fischer
Directeur Général chez APEPTICO Forschung & Entwicklung GmbH
Profil
Bernhard Fischer is the founder and the Chief Executive Officer of APEPTICO Forschung & Entwicklung GmbH, which was founded in 2008.
He also held former positions as a Principal at FIBREX Medical, Inc., Avidis SA, Sandoz GmbH, Baxter Vaccine AG, and Novartis Austria GmbH.
Postes actifs de Bernhard Fischer
| Sociétés | Poste | Début |
|---|---|---|
APEPTICO Forschung & Entwicklung GmbH
 APEPTICO Forschung & Entwicklung GmbH Miscellaneous Commercial ServicesCommercial Services APEPTICO Forschung & Entwicklung GmbH develops and commercializes peptide-based therapeutics. Its products targeting chronic and life-threatening diseases. The firms peptide molecules correspond to validated, pharmacodynamic active structures and domains of well-known proteins and biopharmaceuticals. The company was founded by Franz Knauseder, Bernhard Fischer, Rudolf Lucas and Hermann Mascher in 2008 and is headquartered in Vienna, Austria. | Directeur Général | 05/06/2009 |
Anciens postes connus de Bernhard Fischer
| Sociétés | Poste | Fin |
|---|---|---|
| Avidis SA | Corporate Officer/Principal | - |
FIBREX Medical, Inc.
 FIBREX Medical, Inc. Miscellaneous Commercial ServicesCommercial Services FIBREX Medical Inc. is a development stage bio-pharmaceutical company. Its operational affiliate FIBREX Medical Research & Development GmbH was established in Vienna in February 2001. The company was founded to convert high impact scientific discovery into pharmaceutical products for important diseases. The company aims to become a leader in the development and commercialization of pharmaceuticals targeting fundamental mechanisms of inflammation and tissue injury. While inflammation is highly desirable to defend the organism against foreign particles and infections, it can become harmful and destructive if it runs unchecked. Inflammation-based tissue injury is well known as a major component in the pathogenesis and progression of important diseases such as myocardial infarction, septic and hemorrhagic shock, graft rejection, or rheumatoid arthritis. In addition, endothelial dysfunction in inflamed tissues leads to capillary leak and deleterious edema formation, aggravating organ dysfunction. | Corporate Officer/Principal | - |
Sandoz GmbH
 Sandoz GmbH Pharmaceuticals: MajorHealth Technology Sandoz GmbH manufactures generic pharmaceuticals and biotechnological drugs. Its products includes bio-similars, inhalers, patches, injectables, and oral solids. The company was founded in 1946 and is headquartered in Kundl, Austria. | Corporate Officer/Principal | - |
Novartis Austria GmbH
 Novartis Austria GmbH Pharmaceuticals: MajorHealth Technology Novartis Austria GmbH operates as a holding company, which engages in the development and production of pharmaceutical products. The company was founded on January 30, 2006 and is headquartered in Vienna, Austria. | Corporate Officer/Principal | - |
Baxter Vaccine AG
 Baxter Vaccine AG Pharmaceuticals: MajorHealth Technology Baxter Vaccine AG manufactures vaccines and medical therapies. The firm offers TBE vaccine and a vaccine against group C meningococcal meningitis. It provides Lyme Borreliosis and modified vaccines. The company was founded in 1953 and is headquartered in Vienna, Austria. | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
APEPTICO Forschung & Entwicklung GmbH
APEPTICO Forschung & Entwicklung GmbH Miscellaneous Commercial ServicesCommercial Services APEPTICO Forschung & Entwicklung GmbH develops and commercializes peptide-based therapeutics. Its products targeting chronic and life-threatening diseases. The firms peptide molecules correspond to validated, pharmacodynamic active structures and domains of well-known proteins and biopharmaceuticals. The company was founded by Franz Knauseder, Bernhard Fischer, Rudolf Lucas and Hermann Mascher in 2008 and is headquartered in Vienna, Austria. | Commercial Services |
Baxter Vaccine AG
Baxter Vaccine AG Pharmaceuticals: MajorHealth Technology Baxter Vaccine AG manufactures vaccines and medical therapies. The firm offers TBE vaccine and a vaccine against group C meningococcal meningitis. It provides Lyme Borreliosis and modified vaccines. The company was founded in 1953 and is headquartered in Vienna, Austria. | Health Technology |
Sandoz GmbH
Sandoz GmbH Pharmaceuticals: MajorHealth Technology Sandoz GmbH manufactures generic pharmaceuticals and biotechnological drugs. Its products includes bio-similars, inhalers, patches, injectables, and oral solids. The company was founded in 1946 and is headquartered in Kundl, Austria. | Health Technology |
Novartis Austria GmbH
Novartis Austria GmbH Pharmaceuticals: MajorHealth Technology Novartis Austria GmbH operates as a holding company, which engages in the development and production of pharmaceutical products. The company was founded on January 30, 2006 and is headquartered in Vienna, Austria. | Health Technology |
FIBREX Medical, Inc.
FIBREX Medical, Inc. Miscellaneous Commercial ServicesCommercial Services FIBREX Medical Inc. is a development stage bio-pharmaceutical company. Its operational affiliate FIBREX Medical Research & Development GmbH was established in Vienna in February 2001. The company was founded to convert high impact scientific discovery into pharmaceutical products for important diseases. The company aims to become a leader in the development and commercialization of pharmaceuticals targeting fundamental mechanisms of inflammation and tissue injury. While inflammation is highly desirable to defend the organism against foreign particles and infections, it can become harmful and destructive if it runs unchecked. Inflammation-based tissue injury is well known as a major component in the pathogenesis and progression of important diseases such as myocardial infarction, septic and hemorrhagic shock, graft rejection, or rheumatoid arthritis. In addition, endothelial dysfunction in inflamed tissues leads to capillary leak and deleterious edema formation, aggravating organ dysfunction. | Commercial Services |
| Avidis SA | Health Technology |
